Secukinumab: In psoriasis and beyond

被引：0
作者：
Bubna, Aditya K. [1 ]
Viplav, Vinayak [1 ]
机构：
[1] Katihar Med Coll, Dept Dermatol, Katihar 854106, Bihar, India
来源：
JOURNAL OF EGYPTIAN WOMENS DERMATOLOGICAL SOCIETY | 2025年 / 22卷 / 01期
关键词：
hidradenitis suppurativa; off-label dermatologic indications; psoriasis; secukinumab; ORAL LICHEN-PLANUS; HIDRADENITIS SUPPURATIVA; PALMOPLANTAR PSORIASIS; PYODERMA-GANGRENOSUM; CONTROLLED-TRIAL; DOUBLE-BLIND; TH17; EFFICACY; THERAPY; SAFETY;
D O I：
10.4103/jewd.jewd_80_23
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Secukinumab is an IL-17A antagonist, approved by the FDA for the treatment of adult and pediatric (>= 6 years) psoriasis, psoriatic arthropathy, and hidradenitis suppurativa. Of late, secukinumab has been found to be beneficial in pityriasis rubra pilaris, pyoderma gangrenosum, lichen planus, and Beh & ccedil;et's disease. This review will throw light on secukinumab's utility in psoriasis, as well as other dermatologic conditions.
引用
收藏
页码：1 / 12
页数：12
相关论文
共 50 条
[31]   Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis [J].
Frieder, Jillian ;
Kivelevitch, Dario ;
Menter, Alan .
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2018, 9 (01) :5-21
[32]   Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis [J].
Wong, Ian T. Y. ;
Shojania, Kam ;
Dutz, Jan ;
Tsao, Nicole W. .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) :153-166
[33]   Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study [J].
Foley, Peter ;
Tsai, Tsen-Fang ;
Rodins, Karl ;
Hamadah, Issam Ribhi ;
Ammoury, Alfred ;
Dayem, Hussein Abdel ;
Abdallah, Mahmoud ;
Crowe, Susanne ;
Haas, Silvia ;
Pournara, Effie ;
Jagiello, Piotr ;
Huang, Yu-Huei .
DERMATOLOGY AND THERAPY, 2022, 12 (02) :511-527
[34]   Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch [J].
Ohtsuki, Mamitaro ;
Morita, Akimichi ;
Igarashi, Atsuyuki ;
Imafuku, Shinichi ;
Tada, Yayoi ;
Fujita, Hiroyuki ;
Fujishige, Ayako ;
Yamaguchi, Masako ;
Teshima, Rie ;
Tani, Yumiko ;
Nakagawa, Hidemi .
JOURNAL OF DERMATOLOGY, 2017, 44 (10) :1105-1111
[35]   Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis [J].
Ikuma, Daiuske ;
Oguro, Masahiko ;
Hoshino, Junichi ;
Mizuno, Hiroki ;
Sekine, Akinari ;
Kawada, Masahiro ;
Hiramatsu, Rikako ;
Sumida, Keiichi ;
Hasegawa, Eiko ;
Hayami, Noriko ;
Yamanouchi, Masayuki ;
Suwabe, Tatsuya ;
Sawa, Naoki ;
Takaichi, Kenmei ;
Ubara, Yoshifumi .
CEN CASE REPORTS, 2020, 9 (01) :55-58
[36]   Secukinumab (AIN-457) for the treatment of Psoriasis [J].
Jaleel, Tarannum ;
Elmets, Craig ;
Weinkle, Allison ;
Kassira, Sama ;
Elewski, Boni .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) :187-202
[37]   Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre [J].
Laoise Griffin ;
Jennifer Boggs ;
Bart Ramsay ;
Caitriona Hackett ;
Kashif Ahmad ;
Maeve Lynch .
Irish Journal of Medical Science (1971 -), 2021, 190 :639-641
[38]   Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre [J].
Griffin, Laoise ;
Boggs, Jennifer ;
Ramsay, Bart ;
Hackett, Caitriona ;
Ahmad, Kashif ;
Lynch, Maeve .
IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (02) :639-641
[39]   Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence [J].
Wu, Jashin J. ;
Merola, Joseph F. ;
Feldman, Steven R. ;
Menter, Alan ;
Lebwohl, Mark .
DERMATOLOGY AND THERAPY, 2020, 10 (03) :351-364
[40]   Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial [J].
Thaci, Diamant ;
Blauvelt, Andrew ;
Reich, Kristian ;
Tsai, Tsen-Fang ;
Vanaclocha, Francisco ;
Kingo, Kuelli ;
Ziv, Michael ;
Pinter, Andreas ;
Hugot, Sophie ;
You, Ruquan ;
Milutinovic, Marina .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (03) :400-409
12345